Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives $13.80 Average Target Price from Analysts

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) has received an average rating of “Moderate Buy” from the five analysts that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $13.80.

Several research analysts have issued reports on AMRX shares. Piper Sandler reiterated an “overweight” rating and set a $13.00 price objective (up from $11.00) on shares of Amneal Pharmaceuticals in a research note on Friday, October 31st. Truist Financial set a $15.00 target price on shares of Amneal Pharmaceuticals in a research report on Wednesday, January 7th. Weiss Ratings restated a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research report on Wednesday, January 21st. Finally, Barclays initiated coverage on shares of Amneal Pharmaceuticals in a research note on Monday, December 8th. They set an “overweight” rating and a $15.00 price objective on the stock.

Amneal Pharmaceuticals Trading Up 2.5%

NASDAQ AMRX opened at $15.19 on Friday. Amneal Pharmaceuticals has a 1-year low of $6.68 and a 1-year high of $15.42. The company has a market capitalization of $4.78 billion, a price-to-earnings ratio of 759.88 and a beta of 1.36. The stock’s 50 day moving average is $13.40 and its two-hundred day moving average is $11.42.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. AQR Capital Management LLC increased its position in Amneal Pharmaceuticals by 3.2% in the 4th quarter. AQR Capital Management LLC now owns 1,046,112 shares of the company’s stock valued at $13,181,000 after acquiring an additional 32,096 shares in the last quarter. Abel Hall LLC acquired a new position in shares of Amneal Pharmaceuticals during the fourth quarter worth approximately $243,000. Cetera Investment Advisers grew its stake in shares of Amneal Pharmaceuticals by 47.2% during the fourth quarter. Cetera Investment Advisers now owns 21,445 shares of the company’s stock valued at $270,000 after purchasing an additional 6,875 shares during the last quarter. Jain Global LLC increased its holdings in shares of Amneal Pharmaceuticals by 88.9% in the fourth quarter. Jain Global LLC now owns 1,060,916 shares of the company’s stock valued at $13,368,000 after purchasing an additional 499,255 shares in the last quarter. Finally, Amundi bought a new position in Amneal Pharmaceuticals in the 4th quarter worth approximately $573,000. Institutional investors and hedge funds own 31.82% of the company’s stock.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.